The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis

Kopp, Matthias; Brauburger, Jens; Riedinger, Frank; a, Dorothee Beischer; Ihorst, Gabriele; Kamin, Wolfgang; Zielen, Stefan; Bez, C.; Friedrichs, Frank; Berg, Andrea von; Gerhold, Kerstin; Hamelmann, Eckard; Hultsch, T.; Kuehr, Joachim

doi:10.1067/mai.2002.128804

Cited by 76 publications

(54 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Activation of leukocytes was measured by cellular antigen stimulation test (Buehlmann Laboratories Inc., Allschwil, Switzerland) [27]. Briefly, leukocytes were isolated by dextran sedimentation from EDTA blood.…”

Section: Methodsmentioning

confidence: 99%

Effect of n–3 Polyunsaturated Fatty Acids in Asthma after Low-Dose Allergen Challenge

Schubert

Kitz

Beermann

et al. 2008

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Background: We investigated the anti-inflammatory potential of n–3 polyunsaturated fatty acids (PUFA) on specific bronchial inflammation. Allergic asthmatics were challenged using a low-dose allergen provocation model. Methods: Our parallel double-blinded study randomly assigned 23 house dust mite-allergic asthmatics (aged 22–29 years; 13 females, 10 males) to dietary supplementation with either an n–3 PUFA-enriched fat blend (0.69 g/day) or placebo for 5 weeks. After 3 weeks, the patients were challenged daily with low doses of mite allergen for 2 weeks. Primary outcome parameters were effects on lung function (forced expiratory volume in 1 s, FEV₁) and exhaled nitric oxide (eNO) as a marker of bronchial inflammation. Results: Even before the bronchial challenge, eNO was significantly lower in the n–3 PUFA group (p = 0.014). Levels of eNO increased during allergen exposure in both groups, but differences in means were significantly lower in the n–3 PUFA group (p = 0.022). During the low-dose allergen challenge, there were no differences between the groups with regard to symptoms, FEV₁ or the allergen dose required to induce deterioration of lung function (PD₂₀). Numbers of sputum eosinophils did not differ significantly, while serum eosinophils (10.1 ± 0.1.84 vs. 5.79 ± 0.69%) as well as changes in eosinophilic cationic protein (20.5 ± 9.93 vs. –1.68 ± 4.36 ng/ml) and in vitro cysteinyl leukotriene release (2,889 ± 872 vs. 1,120 ± 173 ng/ml) were significantly lower in the n–3 PUFA group (p < 0.05 each). Conclusion: Our results provide evidence that dietary supplementation with n–3 PUFA is able to reduce bronchial inflammation even after low-dose allergen challenge.

show abstract

Section: Methodsmentioning

confidence: 99%

Effect of n–3 Polyunsaturated Fatty Acids in Asthma after Low-Dose Allergen Challenge

Schubert

Kitz

Beermann

et al. 2008

Int Arch Allergy Immunol

View full text Add to dashboard Cite

show abstract

“…Among these, omalizumab, a humanized monoclonal antibody that binds circulating IgE and prevents its attachment to high-affinity IgE receptors, is the most extensively studied agent approved for the treatment of severe uncontrolled asthma with perennial sensitizations. However, a growing number of reports indicate its effectiveness in seasonal and perennial AR in adults/adolescents [90][91][92][93][94] and children [95][96][97][98][99]. Targeting the early phase of the allergic cascade could prove a significant allergic march-preventing treatment.…”

Section: Other Interventionsmentioning

confidence: 99%

Pediatric Allergic Rhinitis and Asthma: Can the March be Halted?

et al. 2013

View full text Add to dashboard Cite

The strong epidemiologic and pathophysiologic link between allergic rhinitis (AR) and asthma has led to the concept of 'united airways disease' or 'respiratory allergy', implying that allergy, in its widest sense, underlies this clinical syndrome. Progression from AR to asthma is frequent and part of the 'atopic march'. Since pediatric immune responses are more adaptable and therefore may be more amenable to treatment, interventions at early childhood are characterized by a higher chance to affect the natural history of respiratory allergy. Although current treatments are quite effective in alleviating respiratory allergy symptoms, it has proven much more difficult to confirm any influence on the progression of the disease. Much more promising is the field of specific allergen immunotherapy, where current evidence, although not yet of ideal robustness, points towards a disease-modifying effect. In addition, newer or emerging, possibly more effective or more targeted interventions are promising in the preventive sense.

show abstract

“…Als Zusatzbehandlung zu einer spezifischen Immuntherapie (SIT) konnte demonstriert werden, dass diese Kombinationstherapie einer alleinigen SIT überlegen war und dass keine Unterschiede bei der Behandlung von Patienten mit verschiedenen Typ-1-Allergenen (Birke versus Gräser-pollen) evaluiert wurden [46]. In weiteren Untersuchungen wurden zusätzlich immunologische Parameter analysiert und es zeigte sich im Vergleich zur Plazebogruppe, dass sowohl die Anzahl der Eosinophilen im Blut und in der Nasenschleimhaut als auch IgE-Serumlevel und IgE + -Zellen in der Behandlungsgruppe deutlich reduziert waren [47,48].…”

Section: Beeinflussung Allergischer Erkrankungen Durch Anti-ige-antikunclassified

Neue monoklonale Antikörper und ihr Einsatz in der Dermatologie

2003

Akt Dermatol

View full text Add to dashboard Cite

The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis

Cited by 76 publications

References 25 publications

Effect of n–3 Polyunsaturated Fatty Acids in Asthma after Low-Dose Allergen Challenge

Effect of n–3 Polyunsaturated Fatty Acids in Asthma after Low-Dose Allergen Challenge

Pediatric Allergic Rhinitis and Asthma: Can the March be Halted?

Neue monoklonale Antikörper und ihr Einsatz in der Dermatologie

Contact Info

Product

Resources

About